Genentech's Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson's Disease

By: Investing.com

Dec 21 2024
45
9628 Views

Genentech's Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson's Disease

PADOVA study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints
Prasinezumab continues to be well tolerated and no new safety signals w… [+6910 chars]

Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting

Genentech's Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson's Disease

Europe Dental Bone Grafts And Substitutes Market to Set to Surpass Valuation of US$ 494.18 Million By 2032 | Astute Analytica

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Major mistake people make to get yellow teeth even if they brush them twice a day

Connor Clark & Lunn Investment Management Ltd. Acquires 34,599 Shares of Nektar Therapeutics (NASDAQ:NKTR)

Brokerages Set Nektar Therapeutics (NASDAQ:NKTR) Target Price at $3.50

Analysts Issue Forecasts for NKTR Q1 Earnings

Research Analysts Offer Predictions for NKTR FY2024 Earnings

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

Contrasting Aravive (NASDAQ:ARAV) and Nektar Therapeutics (NASDAQ:NKTR)

Share this page

Guest Posts by Easy Branches

anchor links ads by Easy Branches

Genentech's Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson's Disease

Related